Company Overview of Dermira, Inc.
Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and DRM01, a small-molecule sebum inhibitor, which is in Phase IIb clinical trial for the treatment of a...
275 Middlefield Road
Menlo Park, CA 94025
Founded in 2010
Key Executives for Dermira, Inc.
Co-Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $465.0K
Co-Founder, Chief Medical Officer, Director and Member of Science & Technology Committee
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Operating Officer
Total Annual Compensation: $355.0K
Chief Development Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2015.
Dermira, Inc. Key Developments
Dermira, Inc. Licenses DRM04 to Maruho for Hyperhidrosis in Japan
Sep 20 16
Dermira, Inc. announced it has entered into an exclusive license agreement with Maruho Co. Ltd. Pursuant to the terms of the agreement, Dermira has granted Maruho an exclusive license to develop and commercialize DRM04, a topical anticholinergic product candidate currently being developed by Dermira for the treatment of primary axillary hyperhidrosis (excessive underarm sweating), in Japan. Under the terms of the agreement, Dermira will receive an initial $25 million license payment. Dermira also is eligible to receive potential additional payments totaling up to $70 million, contingent on the achievement of milestones associated with submission and approval of a marketing application and certain sales thresholds, as well as royalty payments representing up to a low double-digit percentage of net product sales, in Japan. Maruho is responsible for funding all development and commercial costs for the program in Japan. Until such time, if any, as Maruho elects to establish its own source of supply, Maruho will purchase product supply from Dermira for development and, if applicable, commercial purposes at cost. Subject to discussions with Japanese regulatory authorities, Maruho plans to initiate a Phase 1 clinical trial for DRM04 in Japan. This license agreement between Dermira and Maruho is not subject to the existing Right of First Negotiation Agreement entered into between the parties in 2013, in connection with which Maruho also made an investment in Dermira.
Dermira, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months June 30, 2016
Aug 8 16
Dermira, Inc. reported consolidated earnings results for the second quarter and six months June 30, 2016. For the quarter, the company reported loss from operations of $28,041,000 against $17,343,000 a year ago. Net loss was $27,755,000 against $17,159,000 a year ago. Net loss per basic and diluted share was $0.89 against $0.69 a year ago.
For the six months, the company loss from operations of $56,796,000 against $31,577,000 a year ago. Net loss was $56,191,000 against $31,194,000 a year ago. Net loss per basic and diluted share was $1.84 against $1.26 a year ago.
Dermira Mulls Acquisitions
Jun 8 16
Dermira, Inc. is lloking for acquisitions. The company which has offered 4.5 million common stocks, intends to use the net proceeds for expand business by in-licensing or acquiring, as the case may be, commercial products, product candidates, technologies, compounds, other assets or complementary businesses.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|